HDAC2 overexpression correlates with aggressive clinicopathological features and DNA-damage response pathway of breast cancer

Authors

Wenqi Shan
Yuanyuan Jiang
Huimei Yu
Qianhui Huang
Lanxin Liu
Xuhui Guo
Lei Li
Qing-Sheng Mi, Henry Ford HealthFollow
Kezhong Zhang
Zengquan Yang

Recommended Citation

Shan, W., Jiang, Y., Yu, H., Huang, Q., Liu, L., Guo, X., … Yang, Z. (2017). HDAC2 overexpression correlates with aggressive clinicopathological features and DNA-damage response pathway of breast cancer. American journal of cancer research, 7(5), 1213–1226.

Document Type

Article

Publication Date

1-1-2017

Publication Title

Am J Cancer Res

Abstract

There are 18 lysine deacetylases, also known as histone deacetylases (HDACs), that remove acetyl groups from histone and non-histone proteins, thereby playing critical roles in numerous biological processes. In many human cancers, HDACs are dysregulated through mutation, altered expression, or inappropriate recruitment to certain loci. However, knowledge of the genomic and transcriptomic alterations and the clinical significance of most HDACs in breast cancer remain incomplete. We used TCGA and METABRIC datasets to perform comprehensive, integrated genomic and transcriptomic analyses of 18 HDAC genes in approximately 3000 primary breast cancers and identified associations among recurrent copy number alteration, gene expression, clinicopathological features, and patient survival. We found distinct patterns of copy number alteration and expression for each HDAC in breast cancer subtypes. We demonstrated that

Comments

Creative Commons Attribution Non-Commercial License

PubMed ID

28560068

Volume

7

Issue

5

First Page

1213

Last Page

1226